Jeremy Friedler is an experienced biopharmaceutical consultant with 16 years of strategy and operations experience in supply chain and manufacturing operations for life sciences. He brings deep knowledge and analytical expertise in manufacturing and supply chain management, CMC, cGMP quality and commercial launch planning. Friedler’s work with preclinical, clinical and commercial stage pharmaceutical, biotechnology and cell and gene therapy companies includes addressing a wide range of operations challenges faced by both emerging and established biopharma clients.
Prior to his work with Converge, Friedler spent nearly a decade as a Consultant in the Pharmaceutical & Life Sciences Advisory practice at PricewaterhouseCoopers (PwC) (formerly PRTM), serving large, multinational pharmaceutical companies in addition to mid-sized and emerging biotech companies in supply chain and manufacturing transformation, supply chain and manufacturing operations strategy, and post-merger integration.
Before joining PwC, he was a Consultant in the Strategy & Operations practice of Maxiom Consulting Group. Working primarily with emerging biotech clients, Friedler developed and implemented both commercial and clinical supply chain strategies and supported commercial launch preparation for innovative treatments.
He has also served in industry roles including Supply Chain at ARIAD Pharmaceuticals (now Takeda), where Friedler was responsible for clinical supply chain operations for late state Phase III pipeline assets, in addition to Technical Operations commercial launch planning for ICLUSIG® (ponatinib) for chronic myeloid leukemia. His career began in Supply Chain and External Manufacturing Operations at Alnylam Pharmaceuticals.
Friedler earned his Master’s Degree in Supply Chain Management from Northeastern University and his Bachelor of Arts from Franklin & Marshall College.